BCL2L1 and in situ carcinoma: When the HaCaT cells were treated with PTX + CIS, we found a 1- to 3-fold increase in MCL-1 gene and > 2.5-fold in NOXA, BAD, P65/RELA, PUMA and BCL-XL.